{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.75","upperLimit":"503.75","value":"1.5"},{"groupId":"OG001","lowerLimit":"0.92","upperLimit":"162.58","value":"1.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.47","upperLimit":"503.77","value":"0.92"},{"groupId":"OG001","lowerLimit":"0.5","upperLimit":"503.58","value":"0.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.338","upperLimit":"9.92","value":"0.75"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"1.75","value":"0.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"title":"Steady State (Cycle 6-10)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Tabalumab 100 milligram (mg) administered once intravenously (IV) over 30 minutes on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 milligram per square meter (mg/m\\^2) administered once subcutaneously (SQ) on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"OG000","title":"100 mg Tabalumab+Dexamethasone+Bortezomib"},{"description":"Tabalumab 300 mg administered once IV over 30 minutes on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 mg/m\\^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"OG001","title":"300 mg Tabalumab+Dexamethasone+Bortezomib"}],"paramType":"MEAN","populationDescription":"All randomized participants who received at least 1 dose of study drug with evaluable PK values.","reportingStatus":"POSTED","timeFrame":"C1 D1: Predose, 3O minutes, 2 hours Postdose; C1 D4, 8, 11: Predose, (D11 only, 30 minutes Postdose); C2 and C6-C10 D1: Predose and immediately Postdose; C2 D 4, 8, 11: Anytime","title":"PK: Time to Maximum Plasma Concentration (Tmax) of Tabalumab","type":"SECONDARY","unitOfMeasure":"hours"}